Trial · NCT02470585
Results by group180
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 180
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 22.0 | 95% Confidence Interval 17.8 to 29.1 | months | |
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 21.1 | 95% Confidence Interval 17.0 to 25.5 | months | |
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 34.7 | 95% Confidence Interval 31.8 to NA | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 20.5 | 95% Confidence Interval 17.8 to 22.8 | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 18.1 | 95% Confidence Interval 16.4 to 22.7 | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 31.9 | 95% Confidence Interval 25.8 to 38.0 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 17.3 | 95% Confidence Interval 15.1 to 19.1 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 15.2 | 95% Confidence Interval 14.1 to 17.3 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 3 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 23.5 | 95% Confidence Interval 19.3 to 26.3 | months | |
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 22.0 | 95% Confidence Interval 17.8 to 29.1 | months | |
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 21.1 | 95% Confidence Interval 17.0 to 25.5 | months | |
| Progression-Free Survival (PFS) in the BRCA-deficient Population (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 34.7 | 95% Confidence Interval 31.8 to NA | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 20.5 | 95% Confidence Interval 17.8 to 22.8 | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 18.1 | 95% Confidence Interval 16.4 to 22.7 | months | |
| Progression-Free Survival (PFS) in the Homologous Recombination Deficiency Cohort (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 31.9 | 95% Confidence Interval 25.8 to 38.0 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1) | Placebo + Carboplatin + Paclitaxel -> Placebo | 17.3 | 95% Confidence Interval 15.1 to 19.1 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Placebo | 15.2 | 95% Confidence Interval 14.1 to 17.3 | months | |
| Progression-Free Survival (PFS) in the Intention-to-treat Population (Arm 2 vs Arm 1) | Veliparib + Carboplatin + Paclitaxel -> Veliparib | 23.5 | 95% Confidence Interval 19.3 to 26.3 | months | |
| Overall Survival (OS) in the BRCA-deficient Population | Placebo + Carboplatin + Paclitaxel -> Placebo | 89.5 | 95% Confidence Interval 83.3 to NA | months | |
| Overall Survival (OS) in the BRCA-deficient Population | Veliparib + Carboplatin + Paclitaxel -> Placebo | NA | 95% Confidence Interval 69.3 to NA | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02470585/results